The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Rhythm Pharmaceuticals Pretax Margin % Related Terms
Rhythm Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Rhythm Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RYTM vs MIRM, SYRE, PTGX: Pretax Margin % Comparison
For the Biotechnology subindustry, Rhythm Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Pharmaceuticals Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (MEX:RYTM) has a Pretax Margin % of -91.65% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Rhythm Pharmaceuticals and its competitors. According to the industry distribution chart, Rhythm Pharmaceuticals ranks #474 out of 942 companies in the Biotechnology industry, placing it in the top 50.3%.
Is Rhythm Pharmaceuticals' Pretax Margin % too high?
Rhythm Pharmaceuticals' current Pretax Margin % is -91.65%. Based on the distribution chart, Rhythm Pharmaceuticals ranks #474 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Pretax Margin % compare to MIRM and SYRE?
According to the Biotechnology industry distribution chart, Rhythm Pharmaceuticals ranks #474 out of 942 companies for Pretax Margin %. This places Rhythm Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Pretax Margin % is -91.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Pretax Margin % of -91.65%. The stock's GF Value™ is MXN1,874.87, compared to a current price of MXN1,866.76 — trading 0.4% below its estimated fair value. The current Pretax Margin % is -91.65%. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Pretax Margin % is -91.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN1,866.76 is trading 0.4% below its estimated GF Value™ of MXN1,874.87.
Key valuation signals for MEX:RYTM:
Pretax Margin %: -91.65%
GF Value™: MXN1,874.87 vs. price of MXN1,866.76 (0.4% below fair value)
No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score
Get the complete analysis for MEX:RYTM
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RYTM has been successfully added to your 
